Contact dermatitis · 2011
Lack of effect of ustekinumab in treatment of allergic contact dermatitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bangsgaard Nannie, Zachariae Claus, Menné Torkil, Skov Lone
Аннотация
BACKGROUND: Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL-12 and IL-23, shown to be effective and safe for patients with psoriasis. Despite both IL-12 and IL-23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported.
OBJECTIVES: To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis.
METHODS: A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department.
RESULTS: Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect.
CONCLUSION: Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis.
OBJECTIVES: To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis.
METHODS: A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department.
RESULTS: Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect.
CONCLUSION: Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis.